Other / not listed trials

AI-generated summary

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer is being studied. Conditions: Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer +4 • Eligibility: * INCLUSION CRITERIA: * Participants with an appropriate HLA match for available Surgery Branch KRAS TCRs with evaluable metastatic solid cancer (e.g., gastrointestinal, genitourinary, breast, ovarian, non-small cell…. Goal: Background: Many cancer cells produce substances called antigens that are unique to each cancer. These antigens stimulate the body s immune responses. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors is being studied. Conditions: Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum +30 • Eligibility: Inclusion Criteria: * Age ≥ 36 months and \< 22 years * Pathologically proven malignant cerebellar brain tumor (including medulloblastoma, glioblastoma multiforme, giant cell glioblastoma, anaplastic astrocytoma, primitive…. Goal: This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer is being studied. Conditions: Extensive-stage Small-cell Lung Cancer • Eligibility: Inclusion Criteria: * Have histologically or cytologically confirmed ES-SCLC (using the AJCC \[American Joint Committee on Cancer\] tumor node metastasis staging system combined with Veterans Administration Lung Study…. Goal: This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC). Phase/Status/Sponsor: Unknown phase; RECRUITING; BioNTech SE.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy is being studied. Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma +1 • Eligibility: Inclusion Criteria: 1. Written informed consent and obtained from the subject prior to performing any protocol-related procedures, including screening evaluations. 2. Female patient, age ≥ 18 years. 3.…. Goal: Multicenter, randomized, open label study including patients with advanced HRDpositive high-grade ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary with no residual tumor mass following primary tumor debulking to determine recurrence free survival in patients treated with 3 cycles carboplatin + paclitaxel and maintenance therapy with niraparib vs. 6 cycles carboplatin + paclitaxel and maintenance therapy with niraparib. Phase/Status/Sponsor: Unknown phase; RECRUITING; North Eastern German Society of Gynaecological Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc is being studied. Conditions: Breast Cancer Invasive, Prostate Cancer • Eligibility: Pilot Phase Inclusion Criteria: 1. Spanish speakers of Latinx background as defined by the U.S. Census Bureau as anyone from Mexican, Puerto Rican, Cuban, Dominican, Central or South…. Goal: The study aims to develop educational media interventions to prepare Latinx Spanish-speaking radiation oncology patients for a course of breast or prostate cancer radiation therapy and to foster receptivity and informed decision-making around cancer clinical trial participation. Phase/Status/Sponsor: Unknown phase; RECRUITING; Columbia University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer is being studied. Conditions: Advanced Lung Cancer • Eligibility: Inclusion Criteria: * Aged ≥18 years at the time of giving informed consent. * Histological or cytological confirmed unresectable advanced/metastatic lung cancer. Histological classification may be based on…. Goal: This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC). Phase/Status/Sponsor: Unknown phase; RECRUITING; BioNTech SE.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Male participants with a histologically documented diagnosis of prostate adenocarcinoma. * Newly diagnosed high-risk and very high-risk (localised/locally advanced) prostate cancer or a high-risk biochemical…. Goal: The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally advanced prostate cancer with a breast cancer gene mutation (BRCAm). Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

BBO-11818 in Adult Subjects With KRAS Mutant Cancer is being studied. Conditions: Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma +11 • Eligibility: Inclusion Criteria: * Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation *…. Goal: A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) is being studied. Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer +27 • Eligibility: Inclusion Criteria: * At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval. * Locally advanced or metastatic solid malignancy…. Goal: The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; PMV Pharmaceuticals, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer is being studied. Conditions: Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma • Eligibility: Inclusion Criteria: * Histological or pathological confirmation of metastatic pancreas adenocarcinoma. Cytological or histological evidence of metastatic disease is required. * Male or Female greater than or equal…. Goal: The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed on therapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Engeneic Pty Limited.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors is being studied. Conditions: Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma • Eligibility: Inclusion Criteria: 1. Able to understand and willing to sign the ICF. 2. Male and female subjects of ≥18 years of age. 3. Histologically/cytologically confirmed, locally advanced solid…. Goal: The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above. Phase/Status/Sponsor: Unknown phase; RECRUITING; FBD Biologics Limited.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This phase II randomized trial tests whether giving a PD-1 inhibitor with chemotherapy (gemcitabine–cisplatin) followed by re-irradiation helps people with locally advanced recurrent nasopharyngeal cancer. - It compares immediate re-irradiation after chemo-immunotherapy with a strategy of selective (only certain patients) re-irradiation. - Eligible participants are adults ages 18–70 with local recurrence more than a year after initial treatment, not a candidate for surgery, who achieved complete or partial response after 4–6 cycles of chemo plus PD-1 inhibitor, and have good performance status. - Key exclusions include prior treatment for recurrent NPC or prior PD-1/PD-L1 inhibitors, active autoimmune disease requiring systemic therapy, infections such as HIV/HBV/HCV, interstitial lung disease or significant cardiovascular disease, pregnancy, or other factors that could interfere with participation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The ZANGEA trial tests zanidatamab together with pembrolizumab and chemotherapy in adults with metastatic gastroesophageal adenocarcinoma that is HER2-positive and PD-L1-positive, and who have not had palliative treatment before. - It is an open-label, single-arm phase II study enrolling about 80 patients at roughly 30 sites in Germany and Austria to assess efficacy, safety, tolerability, and quality of life. - The study also includes exploratory aims to compare results with a historical regimen and to identify molecular biomarkers that predict response or toxicity. - Key exclusions include untreated CNS metastases, active autoimmune disease, prior anti-HER2 therapy for GEA, certain infections, and pregnancy or breastfeeding.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works in Patients With Recurrent Glioblastoma is being studied. Conditions: Recurrent Glioblastoma • Eligibility: Inclusion Criteria: * Adults, 18-75 years of age at the time of giving informed consent. Local laws will be followed if the age at consent is older. *…. Goal: This multi-site Phase II study will enroll adults with histologically confirmed diagnosis of World Health Organization (WHO) Grade IV glioblastoma (GBM) consistent with WHO central nervous system (CNS) 2021 criteria who have received prior first-line treatment including with at least radiotherapy and temozolomide, with a Karnofsky performance status (KPS) ≥60, adequate organ function, and at least one measurable lesion according to the response assessment in neuro-oncology (RANO) 2.0 criteria. Phase/Status/Sponsor: Unknown phase; RECRUITING; BioNTech SE.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma is being studied. Conditions: Follicular Lymphoma, Marginal Zone Lymphoma • Eligibility: Inclusion Criteria: 1. For inclusion in Cohorts 1 and 4 patients should have relapsed/refractory, biopsy-proven grade 1, 2 or 3A, FL or MZL, ECOG performance status 0 to…. Goal: The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL Phase/Status/Sponsor: Unknown phase; RECRUITING; Enterome.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests Puxi-Sam (puxitatug samrotecan) as a single-drug treatment versus doctors’ choice of chemotherapy (doxorubicin or paclitaxel) for people with B7-H4–selected advanced or metastatic endometrial cancer that has progressed after platinum-based therapy and anti-PD-1/PD-L1 therapy. It is a phase III, randomized, multicenter global study enrolling about 700 participants in a 1:1 ratio. The study aims to find out if Puxi-Sam can help people live longer without their cancer getting worse or live longer overall, and how it affects safety and quality of life. Key exclusions include uterine sarcomas or neuroendocrine carcinoma, prior TOP1 inhibitor therapy or Puxi-Sam/B7-H4 therapies, active or a history of ILD/pneumonitis or autoimmune disorders, and more than 12 months since completing platinum therapy in the curative setting without additional platinum.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Surgery and Radiotherapy in People With Breast Cancer is being studied. Conditions: Metastatic Breast Cancer, HER2-positive Breast Cancer • Eligibility: Inclusion Criteria: * Age ≥ 18 years. * Pathologically-confirmed metastatic breast cancer. * Oligometastatic breast cancer (≤5 discrete metastatic lesions) without CNS involvement; as seen on standard imaging…. Goal: The researchers are doing this study to see if the combination of surgery, locoregional radiation therapy, SBRT (stereotactic body radiation therapy), and the usual approach is more effective in treating oligometastatic HER2-positive breast cancer than the usual approach alone. The researchers will also study the side effects of the study treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study is being studied. Conditions: Pancreatic Cancer, PD-L1, PD-1 Inhibitor +2 • Eligibility: Inclusion Criteria: * Age ≥ 18 years, regardless of gender; * ECOG score of 0 to 1; * Patients with histologically or cytologically confirmed pancreatic malignancy; * No…. Goal: To investigate the activating effect of local lesion low-dose radiotherapy (2Gy) on the tumor immune microenvironment, and the efficacy, safety, and feasibility of its combination with pembrolizumab and standard therapy in patients with advanced pancreatic cancer. Concurrently, to preliminarily establish an efficacy prediction model for the early identification of patient populations who would benefit from the treatment, thereby providing a theoretical foundation for the implementation of precision medicine. Phase/Status/Sponsor: Unknown phase; RECRUITING; Zhejiang Provincial People's Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests an anti-PD-1 antibody by itself or in combination with low-dose decitabine and/or chemotherapy in people whose cancers have relapsed or are refractory to treatment. - It aims to assess safety and feasibility, as well as any anti-tumor activity and immune effects of the treatment. - Eligible participants are aged 12 to 75 with confirmed relapsed or refractory cancers, including non-Hodgkin lymphoma, Hodgkin lymphoma, gastrointestinal cancers, hepatocellular carcinoma, breast cancer, ovarian cancer, lung cancer, renal-cell cancer, pancreatic cancer, or bile duct cancer, and they must have had at least two prior chemotherapy regimens with adequate organ function. - The study also plans exploratory analyses to identify biomarkers and immune parameters related to response and toxicity. - The study is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- SCR-ESCC-01 tests adding low-dose radiotherapy (LDRT) and conventional radiotherapy (CFRT) to first-line PD-1–based immunochemotherapy for metastatic esophageal squamous cell carcinoma. - It enrolls adults with metastatic ESCC (stage IVB, M1), ECOG 0-1, and no prior anti-tumor therapy. - The trial has a safety run-in of about 20–25 patients, then a randomized phase comparing Arm A (PD-1 inhibitor + chemotherapy + LDRT/CFRT) to Arm B (PD-1 inhibitor + chemotherapy alone). - The primary goal in the randomized phase is median progression-free survival, with safety evaluated in the run-in. - Key exclusions include prior esophageal cancer treatment, active autoimmune disease, high risk of GI bleeding or esophageal fistula, significant interstitial lung or cardiac disease, pregnancy, or recent other cancers.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy is being studied. Conditions: Cancer Of Prostate • Eligibility: * INCLUSION CRITERIA: * Participants must have histologically or cytologically confirmed localized intermediate or high risk prostate cancer: * Intermediate risk - Gleason 7 disease, PSA less than…. Goal: Background: Prostate cancer is often treated with radiation and ADT (ADT is androgen deprivation therapy). Up to 30% of these cancers recur within 5 years of treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests precision-based immunotherapy approaches for primary liver cancer (hepatocellular carcinoma and cholangiocarcinoma) and aims to build a biospecimen repository to study the biology of the cancer and how patients respond to treatment. - It will enroll adults 18 and older with liver cancer who are receiving or planning to receive immunotherapy, and will collect medical records, imaging, tumor tissue, and samples such as blood, urine, and stool over time. - Researchers will perform a wide range of analyses (genomics, epigenetics, metabolomics, microbiome, and immune monitoring) to identify factors that predict response or resistance to immunotherapy and to understand disease progression. - HIV infection is an exclusion criterion, and the study is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether adding pembrolizumab, an immunotherapy drug, to the usual platinum-based chemotherapy after surgery helps people with certain stages of non-small cell lung cancer live longer without the cancer returning. - It is for adults who have had complete surgical removal of stage IIA-IIIB NSCLC (T3-4N2) and who have not received prior systemic treatment for this cancer. - The study compares two timing strategies: pembrolizumab after chemotherapy versus pembrolizumab given at the same time as chemotherapy, to see which approach improves disease-free and overall survival and how it affects side effects and quality of life. - Key eligibility notes include no active autoimmune disease requiring systemic therapy in the past 2 years, no active infection or pneumonitis, not pregnant, and adequate organ function; people with controlled HIV may participate under certain conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy is being studied. Conditions: Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes +1 • Eligibility: Inclusion Criteria: * PHASE 1: Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 (Karnofsky \>= 70%) * PHASE 2: ECOG performance status =\< 2 (Karnofsky \>= 60%)…. Goal: This phase I/II trial studies the best dose of M3814 when given together with radium-223 dichloride or with radium-223 dichloride and avelumab and to see how well they work in treating patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Inspiratory Muscle Training for Breast Cancer Patients on Chemotherapy is being studied. Conditions: Early Stage Breast Carcinoma, Dyspnea • Eligibility: Inclusion Criteria: * Age ≥ 18 years * Within 3 weeks of starting chemotherapy for an early-stage breast cancer diagnosis * Able to exercise independently without needing support…. Goal: This clinical trial studies whether breathing exercises for the muscles that help with breathing air in, inspiratory muscle training (IMT), works to improve breathing muscle strength, shortness of breath, and physical activity levels in women who are receiving chemotherapy for early-stage breast cancer (BC). Cancer and/or treatments for BC can directly result in muscle wasting that involves breathing muscles, skeletal muscles or heart muscles. Phase/Status/Sponsor: Unknown phase; RECRUITING; Ohio State University Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests the safety and potential benefit of giving pembrolizumab (an immunotherapy) with preoperative radiation and intraoperative radiation therapy (IORT) before and during salvage surgery for persistent or recurrent head and neck squamous cell carcinoma that can be removed surgically. It has three arms comparing different timing and doses of radiation around the surgery, all with pembrolizumab around the operation. Researchers will look at toxicity, locoregional tumor control, progression-free survival, and possible biomarkers (like PD-L1, TNF-alpha, NF-kB, tumor mutational burden) plus quality of life. Eligible participants are adults with resectable persistent or recurrent head and neck cancer, but key exclusions include prior immune checkpoint therapy, active autoimmune disease, HIV/HBV/HCV infection, unresectable disease, distant metastases, pregnancy, or breastfeeding.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT) is being studied. Conditions: Intrahepatic Cholangiocarcinoma, Chemotherapy Effect • Eligibility: Inclusion Criteria: 1. Intra-hepatic cholangiocarcinoma. Diagnosis confirmed by biopsy, cytology or previous resection. 2. Not amenable for upfront resection. Defined as: 1. A tumour that is technically not…. Goal: Patients with intrahepatic cholangiocarcinoma (IHC) have relatively aggressive tumors, and the prognosis for most of these patients is dismal. Surgery is the only option that can offer potential cure, but only an estimated 20-25 % are amenable to resection. Phase/Status/Sponsor: Unknown phase; RECRUITING; Oslo University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests whether infusing universal donor NK cells that are TGFβ-imprinted and expanded outside the body, with the chemotherapy gemcitabine and docetaxel, is safe and could improve outcomes for relapsed or refractory pediatric sarcomas. It enrolls children and young adults aged 2 to 40 with measurable relapsed or refractory osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, or other soft tissue sarcomas. Researchers aim to learn about safety and efficacy, the 6-month progression-free survival, and how long the NK cells persist and relate to outcomes. Key exclusions include prior cellular therapies (such as CAR-T), active CNS metastases, pregnancy, HIV infection, and use of other investigational drugs.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors is being studied. Conditions: Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer • Eligibility: Core Inclusion Criteria: * Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. * Provision…. Goal: This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL is being studied. Conditions: T-cell Acute Lymphoblastic Leukemia • Eligibility: Inclusion Criteria: * Patient must have documented T cell ALL and must be in first or later hematologic CR or CRi after a minimum of 2 blocks of…. Goal: In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Eastern Cooperative Oncology Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC is being studied. Conditions: ICC, Advanced Cancer • Eligibility: Inclusion Criteria: 1. Age: Age ≥ 18 years old. 2. Diagnosis: Advanced unresectable intrahepatic cholangiocarcinoma (ICC) diagnosed by histology or imaging. 3. Measurable lesion: At least one measurable…. Goal: Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis. The aim of this study is to investigate the efficacy and safety of GP-HAIC combined with immunosuppressants in the treatment of initially unresectable ICC patients, as well as its role in conversion therapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Eastern Hepatobiliary Surgery Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients is being studied. Conditions: NSCLC • Eligibility: Inclusion Criteria: * Age ≥ 18 years of age at time of consent * ECOG performance status score of ≤2 * Advanced non-small cell lung cancer to meet…. Goal: This is a Single arm, Simon's two stage pilot study in which patients with Non-Small Cell Lung Cancer (NSCLC) with metastatic disease 2L and beyond will receive OncoChoice-informed chemotherapy following National Cancer Care Network (NCCN) treatment guidelines on dosage and scheduling for NSCLC FDA approved drugs. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Illinois at Chicago.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers is being studied. Conditions: Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer • Eligibility: Key Inclusion Criteria: 1. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 2. Histological diagnosis of epithelial ovarian, primary peritoneal, or fallopian tube cancer according to World…. Goal: This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to treat epithelial ovarian, primary peritoneal or fallopian tube cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Regeneron Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma is being studied. Conditions: Follicular Lymphoma • Eligibility: Inclusion Criteria: Eligible subjects will be considered for inclusion if they meet all of the following criteria: * Men and women 18 years of age or older *…. Goal: To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL. Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer is being studied. Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma • Eligibility: Inclusion Criteria: * Participant is considered an adult according to local regulation at the time of signing the informed consent form (ICF). * Female participant is not pregnant,…. Goal: Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Astellas Pharma Global Development, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: * Histological diagnosis of high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. * Have platinum-resistant disease. * Participants who have only had 1 line…. Goal: The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression. Phase/Status/Sponsor: Unknown phase; RECRUITING; Incyte Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Phase 2 Inclusion Criteria: 1. Age ≥ 18 years. 2. Able to understand and provide a signed informed consent that fulfills the relevant IRB or IEC guidelines. 3.…. Goal: This study consists of 2 portions. The phase 2 portion is an open-label, single-arm study to evaluate the safety and efficacy of NAI, PD-L1 t-haNK, and bevacizumab combination therapy in participants with recurrent or progressive GBM. Phase/Status/Sponsor: Unknown phase; RECRUITING; ImmunityBio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial compares rilvegostomig plus gemcitabine and cisplatin versus durvalumab plus gemcitabine and cisplatin as first-line treatment for advanced biliary tract cancer. - It is for adults with unresectable locally advanced or metastatic BTC, including intrahepatic or extra-hepatic cholangiocarcinoma and gallbladder cancer, who have not yet received systemic therapy for advanced disease and have measurable disease with good performance status. - The study aims to learn which regimen provides better efficacy and acceptable safety when used at the start of treatment. - Key exclusions include ampullary cancer, prior systemic therapy for unresectable or metastatic BTC, prior exposure to immune-targeting therapies, active autoimmune disease requiring steroids, and certain interstitial lung disease or serious skin conditions. - Sponsor: AstraZeneca; Status: Recruiting; Phase: Unknown.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery is being studied. Conditions: Mucosal Melanoma, PD-L1 Positive • Eligibility: Inclusion Criteria: 1. Sign a written informed consent form (Informed Consent, ICF) and be able to comply with the visit schedule and related procedures outlined in the protocol.…. Goal: Melanoma has emerged as the fastest-growing malignancy in recent years, with incidence and mortality rates among both men and women in East Asian countries exceeding the Asian average. China ranks fifth among East Asian nations in melanoma incidence. Phase/Status/Sponsor: Unknown phase; RECRUITING; The First Hospital of Jilin University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India is being studied. Conditions: Hodgkin Lymphoma • Eligibility: Inclusion Criteria 1. Treatment-naïve, Hodgkin lymphoma (HL) participants with Ann Arbor Stage 3 or 4 disease. Note: Participants must have histologically confirmed classical HL according to the current…. Goal: The main aim of this study is to check how safe brentuximab vedotin is in adults with untreated Hodgkin Lymphoma (HL) when given together with doxorubicin (Adriamycin), vinblastine and dacarbazine therapy ('AVD'). Another aim is to learn how well treatment of brentuximab vedotin plus AVD works. Phase/Status/Sponsor: Unknown phase; RECRUITING; Takeda.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) is being studied. Conditions: Colorectal Neoplasms • Eligibility: The main inclusion and exclusion criteria include but are not limited to the following: Inclusion Criteria: Inclusion Criteria include, but are not limited to: * Has a histologically…. Goal: In this study, Chinese participants with MSI-H or dMMR advanced colorectal cancer will be assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for treatment. There is no hypothesis testing for this study. Phase/Status/Sponsor: Unknown phase; RECRUITING; Merck Sharp & Dohme LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests lurbinectedin used alone to treat pediatric and young adult participants with relapsed or refractory Ewing sarcoma (and, in Phase 1, other previously treated solid tumors). The trial has two parts: Phase 1 will look at safety, tolerability, how the drug behaves in the body, the recommended Phase 2 dose, and initial effectiveness; Phase 2 will further assess how well it works and its safety in the target group. Eligible participants are children and young adults roughly aged 2 to 30 with a confirmed solid tumor and adequate organ function and general health. Important exclusions include QT prolongation, active CNS metastases requiring steroids, significant uncontrolled illness or recent intensive therapy, prior lurbinectedin or trial drugs, and recent live vaccines.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma is being studied. Conditions: Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III • Eligibility: Screening Inclusion Criteria for Phase 1 and Phase 2: * Signed written informed consent approved before undertaking any study-specific procedures. * Age ≥18 years of age. * Willing…. Goal: The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and to characterize the safety and tolerability of these combinations in adult participants with glioblastoma (GBM). Arm B which was previously added to the protocol, has been permanently halted per the safety monitoring committees' decision on the safety findings of this arm. Phase/Status/Sponsor: Unknown phase; RECRUITING; Debiopharm International SA.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests a total neoadjuvant therapy plan that starts with induction immunochemotherapy and is followed by chemoradiotherapy before surgery for locally advanced esophageal squamous cell carcinoma. It is for adults aged 18 to 75 with intrathoracic ESCC, good performance status (ECOG 0–1), and adequate organ function whose disease meets locally advanced criteria. The study aims to learn whether this approach improves systemic control, downstages the tumor, and reduces recurrence and metastasis after surgery. Key exclusions include adenocarcinoma, prior thoracic irradiation or chemotherapy, prior anti-PD-1/PD-L1 therapy, active autoimmune disease or infections, HIV, active hepatitis B or C, pregnancy, and other major medical conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prevention of Postoperative Pancreatic Fistula Following Pancreaticoduodenectomy by Preoperative Radiotherapy : a Phase 2 Trial is being studied. Conditions: Pancreatic Fistula, Pancreaticoduodenectomy • Eligibility: Inclusion Criteria: * Aged ≥ 45 years old * Candidate for pancreaticoduodenectomy by laparotomy * Body mass index (BMI) ≥ 25kg/m2 * Diameter of main pancreatic duct (MPD)…. Goal: Design of the study Prospective, single arm, multicentric, phase II open trial Number of participating sites 14 French centers of HPB Surgery departments associated with 14 Radiation Oncology Departments. Implementation of the study A screening of eligible patients will be made locally by the referring surgeon of each centre based on patient medical records. Phase/Status/Sponsor: Unknown phase; RECRUITING; Assistance Publique - Hôpitaux de Paris.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses is being studied. Conditions: Adjustment Disorder • Eligibility: Inclusion Criteria: * Has a ≥4 week history of AjD as defined by DSM-5-TR with either depressed mood, or mixed anxiety and depressed mood confirmed by clinical interview…. Goal: The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo. Phase/Status/Sponsor: Unknown phase; RECRUITING; Reunion Neuroscience Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies is being studied. Conditions: Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma +1 • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years 2. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 3. Histologically confirmed diagnosis of any of the following: • Gastric or…. Goal: The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric cancer and other GI malignancies is an area of great unmet need. Phase/Status/Sponsor: Unknown phase; RECRUITING; Anwaar Saeed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers is being studied. Conditions: Pancreatic Cancer, Renal Cell Cancer, Breast Cancer +2 • Eligibility: * INCLUSION CRITERIA: * For Phase I: Evaluable, unresectable cancer expressing CD70 as assessed by immunohistochemistry of resected tissue (greater than or equal to 2+ CD70 positive on…. Goal: Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer is being studied. Conditions: Epithelial Ovarian Cancer • Eligibility: Key Inclusion criteria * Participants with confirmed diagnosis of high-grade serous EOC, primary peritoneal cancer, or fallopian tube cancer. * Participants must have platinum-resistant disease: * Participants who…. Goal: The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FRα levels. Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests whether intensity-modulated proton therapy (IMPT) reduces side effects while maintaining or improving cancer control compared with intensity-modulated photon radiotherapy (IMRT) in nasopharyngeal cancer. It is for adults aged 18 to 70 with newly diagnosed high-risk locoregionally advanced nasopharyngeal carcinoma (WHO type II/III, T4 or N3, M0). After induction chemotherapy, all participants receive concurrent chemoradiotherapy with immunotherapy and are randomized 1:1 to IMPT or IMRT during that phase. The study aims to learn about acute grade ≥3 toxicities and 3-year progression-free survival, along with other outcomes like overall survival and quality of life; key exclusions include distant metastasis (M1), prior NPC therapy, active autoimmune disease, pregnancy, and allergy to study medications.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 is being studied. Conditions: Melanoma, Metastatic Melanoma, Advanced Solid Tumor +1 • Eligibility: Inclusion Criteria: Patients are eligible for inclusion in the study only if they meet all of the following criteria: 1. Patient has received at least 1 dose of…. Goal: This is a noninterventional, observational, long-term follow-up (LTFU) study. Patients in this study will be followed for 5 years from enrollment on this study to assess potential delayed risks of RPx products. Phase/Status/Sponsor: Unknown phase; RECRUITING; Replimune Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Children's Laughter and Fun Yoga as Adjunctive Pain Relief Following Chemotherapy. is being studied. Conditions: Acute Lymphoblastic Leukemia ALL • Eligibility: Inclusion Criteria: * Children aged 2-10 years. * Medically diagnosed with acute lymphoblastic leukemia (ALL) and currently receiving chemotherapy that includes dexamethasone pulses during the maintenance phase. *…. Goal: The goal of this clinical trial is to learn if a home-based program that combines laughter and fun yoga can help lower pain in children receiving chemotherapy. The study focuses on children with acute lymphoblastic leukemia who experience pain during treatment with chemotherapy and steroids. Phase/Status/Sponsor: Unknown phase; RECRUITING; Bahaa Bou Dargham.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing is being studied. Conditions: Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer +7 • Eligibility: * INCLUSION CRITERIA: * Participants with a locally advanced or metastatic pathologically confirmed cancer whose NCI Licensed Independent Practitioner (LIP) determined they are candidates for treatment with atezolizumab,…. Goal: Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune system fight cancer by blocking proteins that cause cancer cells to grow. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests how cancers develop in people with inherited germline mutations in BAP1 or other cancer-predisposition genes, including mesothelioma patients and their family members. - It has two groups: Cohort 1 includes people with mesothelioma and a confirmed germline mutation; Cohort 2 includes people who carry a BAP1 mutation without mesothelioma or have relatives at risk. - Researchers will collect medical and family histories, do genetic testing, and follow participants with exams, imaging, possible tumor tissue testing, and regular follow-up by phone or visits to learn about cancer risk and disease patterns. - Eligibility requires age 2 or older for certain mutations, and there are no listed exclusions for genetic testing or surveillance.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests PULSAR together with dual immune checkpoint inhibitors (PD-1 and CTLA-4 antibodies) and gemcitabine/cisplatin (GC) chemotherapy in people with locally advanced or metastatic cholangiocarcinoma. - It is for adults aged 18 to 75 who have at least one measurable tumor and can receive radiotherapy, immunotherapy, and chemotherapy. - The study aims to determine how well the combination works and how safe it is, and to learn about its effects on the tumor environment and the body's immune response. - Key exclusions include prior anti-PD-1/PD-L1 therapy, active autoimmune diseases (with some exceptions), active infections or HIV/HCV, and having previously received systemic therapy for cholangiocarcinoma. - The trial is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a single-arm, multi-center trial testing romiplostim as a supportive care measure for patients with a new diagnosis of Ewing sarcoma receiving interval‑compressed chemotherapy. - It aims to learn whether romiplostim can prevent chemotherapy-induced thrombocytopenia (low platelets), whether it is safe to use with upfront Ewing sarcoma treatment, and whether it can be feasibly incorporated into standard regimens. - Eligible participants are patients over 1 year old with a new Ewing sarcoma diagnosis who are treated with interval‑compressed chemotherapy, and their informed consent (and assent when appropriate) is required. - Key exclusions include bone marrow–metastatic disease, certain extensive bone marrow–directed radiation or procedures, prior use of romiplostim or other platelet‑producing agents, and a history of immune thrombocytopenia–related treatments or related hematologic conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer is being studied. Conditions: Locally Advanced Pancreatic Adenocarcinoma • Eligibility: Inclusion Criteria: 1. Patient aged from 18 to 75 years at the date of signature of the consent form 2. Histologically or cytologically proven pancreatic adenocarcinoma 3. Eastern…. Goal: The aim of this study is to demonstrate the efficacy of intensified and sequential chemotherapy (Gabrinox) comprising Gembrax regimen (Gemcitabine-Abraxane) followed by the Folfirinox regimen (5FU, Oxaliplatin and Irinotecan) in patients with locally advanced pancreatic adenocarcinoma. The study will also demonstrate the feasibility of combining this intensified chemotherapy with MRI-guided stereotactic radiotherapy in non-progressive patients after the chemotherapy by Gabrinox regimen. Phase/Status/Sponsor: Unknown phase; RECRUITING; Institut du Cancer de Montpellier - Val d'Aurelle.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma is being studied. Conditions: Cholangiocarcinoma, IDH Mutation • Eligibility: Inclusion Criteria: 1. Patient\* provides signed informed consent. 2. Patient is ≥ 18 years at the time of given informed consent. 3. Patient has histologically documented curatively resected…. Goal: This study trial is a prospective, multicentre, exploratory, single-arm, open-label phase II study to evaluat ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma Phase/Status/Sponsor: Unknown phase; RECRUITING; Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests a three‑drug combo—Apatinib, Adebrelimab, and GEMOX chemotherapy—for adults with unresectable intrahepatic cholangiocarcinoma (ICC). It aims to see if this regimen can achieve more tumor shrinkage and longer survival, while keeping an eye on safety, compared with historical data for chemotherapy alone. Eligible participants are adults 18–75 with confirmed ICC that cannot be removed by surgery or has progressed after prior treatment, and who have good liver function and performance status. Up to 38 people will be enrolled at multiple hospitals; key exclusions include prior immune checkpoint inhibitor treatment, having another active cancer, and conditions like significant ascites or uncontrolled medical issues.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma is being studied. Conditions: IDH-Wildtype Glioblastoma, Glioblastoma (GBM) • Eligibility: Inclusion Criteria: * 18 years of age or older * Newly diagnosed IDH-wildtype glioblastoma * Completed maximal safe brain tumor resection * Completed post-operative brain RT * Plan…. Goal: The body's biological functions follow a circadian rhythm, meaning that individual biological functions in the body change over a 24-hour cycle. There is evidence suggesting that the body and cancer cells may react differently to anti-cancer treatment based on the time of day they are exposed. Phase/Status/Sponsor: Unknown phase; RECRUITING; Ottawa Hospital Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests adding lenvatinib to nivolumab plus chemotherapy for gastric cancer with peritoneal metastasis and malignant ascites. - It is for adults with newly diagnosed or recurrent/metastatic gastric or GEJ adenocarcinoma who have peritoneal metastasis with grade ≥2 ascites and a PD-L1 CPS ≥5. - The study aims to learn about the safety and efficacy of this combination and whether it can improve outcomes, such as survival, in this group. - Key exclusions include uncontrolled illness or infection, pregnancy or breastfeeding, HIV or active hepatitis B/C infection, recent major surgery, and other concurrent cancer therapies.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests amivantamab plus FOLFIRI versus cetuximab/bevacizumab plus FOLFIRI in people with KRAS/NRAS and BRAF wild-type colorectal cancer who have previously received chemotherapy. - It aims to learn whether the amivantamab combination improves progression-free survival and overall survival compared with the cetuximab/bevacizumab combination. - Eligible participants have recurrent, unresectable, or metastatic colorectal cancer with confirmed KRAS/NRAS and BRAF wild-type status, have had at least one prior systemic therapy for metastatic disease, and have ECOG 0–1. - Key exclusions include preexisting interstitial lung disease/pneumonitis, allergies to study drugs, prior exposure to irinotecan or EGFR/MET inhibitors, HER2-positive tumors, or another active malignancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria: 1. Newly-diagnosed, histologically proven, intracranial glioblastoma with maximal safe resection. Biopsy alone is expected if resection is not possible. MGMT promoter methylation status must be tested…. Goal: Currently, the optimal treatment regimen for elderly Glioblastoma (GBM) patients with poor performance status (PS) is unknown. Based on data for elderly GBM patients and the limited data for patients with poor PS, hypofractionated RT or a short course of Temozolomide (TMZ) may provide survival benefit without the added toxicity and inconvenience of a more protracted treatment regimen. Phase/Status/Sponsor: Unknown phase; RECRUITING; AHS Cancer Control Alberta.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. is being studied. Conditions: Gastric Carcinoma • Eligibility: Inclusion Criteria: * Voluntarily consent to participate in the study and sign the informed consent form * Expected survival period \>12 weeks * ECOG Performance Status 0 or…. Goal: The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Trastuzumab and Tislelizumab Versus Chemotherapy Combined with Trastuzumab with or without Pembrolizumab as First-Line Treatment for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma with HER2-high Expression. Phase/Status/Sponsor: Unknown phase; RECRUITING; RemeGen Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Carbon Ion Radiotherapy in Frail Patients With Pancreatic Cancer is being studied. Conditions: Pancreatic Neoplasm • Eligibility: Inclusion Criteria: \- Histologically confirmed pancreatic cancer without distant metastasis. Not eligible for surgery or systemic chemotherapy, defined as: Clinical Frailty Scale (CFS) score ≥ 4, or Significant…. Goal: "This prospective, single-arm phase II study aims to evaluate the efficacy and safety of carbon ion radiotherapy in frail patients with histologically confirmed, non-metastatic pancreatic cancer who are not eligible for surgery or systemic chemotherapy. Frail status is defined as a Clinical Frailty Scale (CFS) score ≥4 or the presence of significant medical comorbidities limiting aggressive treatment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Yonsei University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study in Region Stockholm, Sweden is recruiting adults 18 and older with paraphilic disorders, sexsomnia, or compulsive sexual behavior, and it will compare them to age- and sex-matched healthy controls to learn about clinical features and experiences of violence. Researchers will use medical assessments, interviews, questionnaires, sleep measures, neuropsychological tests, and blood samples to explore psychiatric, sociodemographic, and genetic/epigenetic factors. The study aims to understand how sexual interests develop over time and what the usual treatment looks like, as well as what baseline factors predict treatment outcomes at 3, 6, and 12 months. Eligibility includes consenting adults who understand Swedish and meet DSM-5/ICD-11 criteria for the listed conditions; exclusions include serious mental illness or safety risks, and controls must be free of these conditions and matched for age and sex.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment is being studied. Conditions: Colorectal Neoplasms, Breast Neoplasms, Head and Neck Neoplasms +1 • Eligibility: Inclusion Criteria: * Diagnosis of cancer in either the adjuvant or metastatic setting requiring initial therapy with 5-FU or Capecitabine. * DPYD testing performed by a CLIA-certified laboratory…. Goal: To prospectively evaluate the efficacy and safety of DPYD-guided dosing strategies in a real-world clinical setting, specifically by comparing the incidence of severe (Grade 3 and 4) fluoropyrimidine-related toxicities of heterozygous DPYD variant patients assigned to DPYD-guided reduced dosing versus patients with standard dosing in the control arm. Phase/Status/Sponsor: Unknown phase; RECRUITING; Rutgers, The State University of New Jersey.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung is being studied. Conditions: Cancer, Lung, Metastasis • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years of age. 2. Histologically proven diagnosis of cancer. At a minimum, the lung tumor in consideration for treatment must be clinically…. Goal: The objective of this study is to enhance the safety profile of SAbR in ultra-central tumors of the lung (primary or metastatic) without compromising its effectiveness. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Texas Southwestern Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry is being studied. Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas +40 • Eligibility: Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2,…. Goal: International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massive Bio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer is being studied. Conditions: Metastatic Castration-resistant Prostate Cancer • Eligibility: Key Inclusion Criteria: * Are male adults (defined as ≥18 years of age or of an acceptable age according to local regulations at the time of giving informed…. Goal: This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicines prednisone or prednisolone). The study will include participants with mCRPC that have been previously treated with androgen receptor pathway inhibitor, but with no previous taxane-based systematic chemotherapy for mCRPC. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; BioNTech SE.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer is being studied. Conditions: Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer +3 • Eligibility: Inclusion Criteria: 1. Patients must have a pathologic diagnosis of high grade serous or endometroid epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, FIGO stage III or IV…. Goal: Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadjuvant chemotherapy will not be eligible for iCRS and will be removed from the study. Phase/Status/Sponsor: Unknown phase; RECRUITING; GOG Foundation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. is being studied. Conditions: Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung • Eligibility: Inclusion Criteria: * Histological or cytological diagnosis of advanced, unresectable, and/or metastatic or relapsed/refractory solid tumor. ECOG PS 0 or 1 * Presence of at least 1 measurable…. Goal: The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. Phase/Status/Sponsor: Unknown phase; RECRUITING; Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria for Cohort A and B: * Age ≥70 years. * Eastern Cooperative Oncology Group (ECOG) performance status 0 -2 * Have histologically proven localized or locally…. Goal: The purpose of this study is to evaluate the safety and clinical activity of cemiplimab and the combination of cemiplimab/fianlimab in microsatellite unstable localized or locally advanced colorectal cancer diagnosed in patients age 70 or greater or in patients age 18 or greater considered poor candidates for surgery. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery is being studied. Conditions: Intrahepatic Cholangiocarcinoma • Eligibility: Inclusion Criteria: * Age ≥18 years * ECOG 0-1 * Histologically confirmed intrahepatic cholangiocarcinoma (also variously reported as peripheral cholangiocarcinoma, cholangiolar carcinoma or cholangiocellular carcinoma) (IHC). Confirmation of…. Goal: This study will compare the safety and effects of HAI floxuridine and dexamethasone combined with the standard chemotherapy drugs gemcitabine and oxaliplatin (GemOx) with those of GemOx alone in people with untreated cholangiocarcinoma that cannot be removed with surgery. The researchers want to find out whether the study treatment works better than the standard chemotherapy to delay progression of disease. Phase/Status/Sponsor: Unknown phase; RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide is being studied. Conditions: Glioblastoma, IDH-wildtype • Eligibility: Inclusion Criteria: 1. Provision of signed informed consent for selection and treatment phase obtained from the patient/legal representative prior to performing any protocol-related procedures, 2. Patients must be…. Goal: Tailored approaches targeting crucial oncogenes and pathways have shown successful results in a number of cancer types and offer exciting perspective in neuro-oncology. IDH (Isocitrate dehydrogenase) wild-type (IDHwt) glioblastoma (GBM) (10%) present a unique and homogenous energetic metabolism which is specifically dependent on the oxidative phosphorylation (OXPHOS) rather than on the aerobic glycolysis. Phase/Status/Sponsor: Unknown phase; RECRUITING; Hopital Foch.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC) is being studied. Conditions: Pancreatic Adenocarcinoma • Eligibility: Inclusion Criteria: * A patient will be eligible for inclusion in this study if he or she meets all of the following criteria: 1. 18 years of age…. Goal: Based on a central role of inflammation in pancreas cancer, the role of IL 1 in acute and chronic inflammation , the inhibitory effect of IL 1 alfa and beta by anakinra and preliminary experience with anakinra in combination with chemotherapy in metastasis (with FOLFIRINOX) and localized disease (with gemcitabine/abraxane/cisplatin), a phase 2 study with anakinra in combination with perioperative chemotherapy for patients with PDAC is being proposed. Phase/Status/Sponsor: Unknown phase; RECRUITING; Baylor Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma is being studied. Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma • Eligibility: Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Age between 18 and 39 with body mass index (BMI) ≥ 30 or age…. Goal: This phase II trial tests the safety, side effects, and effectiveness of asparaginase Erwinia chrysanthemi during induction chemotherapy followed by consolidation chemotherapy in treating high-risk adults with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma. Asparaginase Erwinia chrysanthemi, a type of protein synthesis inhibitor, is a drug that is made up of the enzyme asparaginase, which comes from the bacterium Erwinia chrysanthemi, and is used with other drugs in people who cannot take asparaginase that comes from the bacterium E. Phase/Status/Sponsor: Unknown phase; RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer is being studied. Conditions: FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer • Eligibility: Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2. * Histologically or cytologically confirmed diagnosis of epithelial ovarian, primary peritoneal or…. Goal: A Phase 1B/2 Study to Investigate the Safety and Efficacy of TORL-1-23 with Chemotherapy Given Before Initial Surgery in Women with Advanced Stage Ovarian Cancer Phase/Status/Sponsor: Unknown phase; RECRUITING; TORL Biotherapeutics, LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a Phase II, open-label, multicenter study testing whether adding Tislelizumab to induction chemoradiotherapy, followed by planned surgery, can help people with locally advanced unresectable esophageal squamous cell carcinoma. - It is for adults 20 or older whose ESCC is considered unresectable because of tumor or nearby lymph node involvement, and who have good performance status and adequate organ function. - The study aims to learn if this approach improves 2-year overall survival and various measures of tumor response and disease control, including conversion to resectable disease and R0 resection rates, while monitoring side effects. - Key exclusions include prior systemic therapy for advanced ESCC, distant metastases, active infection, autoimmune disease, pregnancy, and recent major surgery or immunosuppressive therapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests a shorter pelvic radiation course (hypofractionation) for women with non-metastatic endometrial cancer. Researchers want to find the safest and most tolerable dose for this shortened treatment. Each daily dose is slightly higher so the total radiation amount is similar to standard treatment. The study is sponsored by the University of Chicago and is currently recruiting; eligible participants are adults with non-metastatic uterine cancer who have had definitive surgery (hysterectomy) and will receive whole-pelvic radiotherapy without concurrent chemotherapy. Exclusions include distant metastases, gross residual disease after surgery, prior pelvic radiation, planned para-aortic nodal irradiation, and certain bowel or ongoing chemotherapy issues.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a pilot study testing whether combining immunotherapy with stereotactic body radiotherapy (SBRT) can shrink unresectable hepatocellular carcinoma (HCC) enough to make surgery possible. It targets adults with HCC that cannot be removed by surgery, including patients with up to three lesions or segmental portal vein involvement, who have relatively preserved liver function and good performance status. The study aims to learn if this downstaging approach allows resection and improves outcomes for HCC patients. Exclusions include prior invasive cancer or prior liver radiotherapy, severe other illnesses, extrahepatic metastases, major vessel thrombosis, ascites or encephalopathy, and SBRT contraindications such as very large tumors (any >15 cm or total tumor sum >25 cm), more than three nodules, or direct extension into the GI tract.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients is being studied. Conditions: Pancreatic Carcinoma Stage II, Cholangiocarcinoma Resectable • Eligibility: Inclusion Criteria: 1. Dated and signed informed consent. 2. Either sex, aged older than 18 years old (inclusive) at date of consent. 3. Subject with a macroscopic resection…. Goal: This is a phase I/II study which intends to characterize the safety, tolerability, and preliminary efficacy of Allogeneic Magicell-NK infusion in PDA or cholangiocarcinoma patients after surgery. Subjects will receive a total of 6 intravenous (IV) infusions of the IP on the 11th day of each chemotherapy cycle. Phase/Status/Sponsor: Unknown phase; RECRUITING; Medigen Biotechnology Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Arm Swelling Occurence in Breast Cancer Patients With Nodal Radiotherapy: Impact of Informing Them of AI-predicted Risk is being studied. Conditions: Unilateral Breast Neoplasms • Eligibility: Inclusion Criteria: 1. Patient must have signed a written informed consent form prior to inclusion visit and to any study specific procedures 2. Women ≥ 18 years 3.…. Goal: Radiotherapy after breast cancer surgery can lead to side effects like arm lymphedema (arm swelling). Lymphedema can cause long-term discomfort and affect quality of life. Phase/Status/Sponsor: Unknown phase; RECRUITING; UNICANCER.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests the long‑term safety of luspatercept in people who have already participated in other luspatercept trials. - It is for adults 18 and older who were in a parent luspatercept study and are either continuing treatment, crossing over from placebo, or entering long‑term follow‑up, and it uses Transition, Treatment, and Follow‑up phases plus a 42‑day safety check after the last dose. - Researchers will monitor safety and track overall survival every 6 months for at least 5 years from the first dose (or 3 years after the last dose, whichever comes later), and watch for progression to AML or other cancers. - Eligible participants must have been in the parent trial, sign informed consent, and meet visit requirements; females on treatment need pregnancy tests and contraception, while males must use a condom with pregnant partners or partners of childbearing potential. - Exclusions include pregnancy or breastfeeding, use of prohibited medications, significant medical or psychological conditions, or other factors that could interfere with safety or study data.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Continuous Monitoring of Prostate Position During Radiotherapy is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Patients undergoing definitive external beam radiotherapy; * Histological proven prostate adenocarcinoma * Prostate Specific Antigen (PSA),within 3 months prior to enrolment * Patient must be…. Goal: This study is investigating measurement of prostate motion during radiotherapy using the implanted gold markers. If motion is greater than 3mm then the beam will be stopped and position corrected (gating). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Royal North Shore Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis is being studied. Conditions: Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III +4 • Eligibility: Inclusion Criteria: * Age ≥ 18 * Stage III/IV skin cancer * Treatment with CTLA-4 inhibitor alone or in combination with PD-1or PD-L1 blockade within the past 8…. Goal: The goal of this clinical trial is to compare the safety and effectiveness of infliximab compared to steroids for the treatment of immune checkpoint inhibitor-induced colitis (ICI colitis) in patients with stage III/IV skin cancer. The main questions this study aims to answer are: * How many patients treated with infliximab experience steroid-free disease resolution after 7 weeks? Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Massachusetts General Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS) is being studied. Conditions: Melanoma Metastatic, Melanoma Recurrent, Cutaneous Melanoma +1 • Eligibility: Inclusion Criteria: * Patients with malignant melanoma (with confirmed histopathological diagnosis) stages III and IV not amenable to locoregional treatment or curative treatment * Measurable disease by RECIST…. Goal: The OTIMAS study is a phase II trial designed to evaluate if the duration of one year of pembrolizumab immunotherapy for advanced metastatic melanoma has equivalent efficacy as the two-year duration of historical controls. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Instituto do Cancer do Estado de São Paulo.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Huaier Granule and Proteinuria is being studied. Conditions: Proteinuria, Breast Cancer Patients • Eligibility: Inclusion Criteria: * \*\*Inclusion Criteria\*\* 1. Female patients aged 18-75 years. 2. Histopathologically confirmed diagnosis of breast cancer. 3. Currently receiving or having a prior history of immunotherapy…. Goal: The goal of this clinical trial is to learn if adding Huaier Granule to standard care can treat proteinuria (excess protein in the urine) in adult female breast cancer patients (aged 18-75) who developed this condition as a side effect of their immunotherapy or anti-angiogenic cancer treatment. The main question it aims to answer is: \* Does the addition of Huaier Granule to standard care improve the effectiveness of proteinuria treatment after 8 weeks? Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Fudan University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests a first-line treatment for unresectable intrahepatic cholangiocarcinoma using FOLFOX-based hepatic arterial infusion chemotherapy with donafenib and pucotenlimab. - It is a prospective, open-label, single-arm phase II study and is not yet recruiting. - The primary goal is to measure the objective response rate, with secondary goals including progression-free survival, overall survival, disease control rate, and safety. - Eligible participants are adults up to 75 years old; key exclusions include prior anti-PD-1/PD-L1 therapy, active CNS metastases, autoimmune disease requiring systemic treatment, active infection, HBV DNA > 2000 IU/mL, HIV, syphilis, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests PET imaging using a radioactive form of methionine to evaluate tumors in children and young adults with cancer. It aims to find out how often MET PET can visualize tumors at diagnosis and whether MET uptake relates to tumor grade. The study also looks at how MET distributes in normal organs and how MET PET findings compare with MRI and FDG-PET CT over time. The trial is sponsored by St. Jude Children’s Research Hospital and is currently active but not recruiting. Eligible participants are patients under St. Jude care with known or suspected cancer; key exclusions include having more than six MET PET scans in the past year or an inability to give informed consent (and lactation in women of childbearing age).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests whether using 3D-PTA drug-sensitivity testing to guide chemotherapy plus capecitabine is better as adjuvant treatment after surgery for stage II/III biliary tract cancers than capecitabine alone. - It is for adults who have had radical surgery for biliary tract cancers (including cholangiocarcinoma and gallbladder cancer) and are fit for chemotherapy (ECOG 0–1). - The study will measure tumor response, safety, quality of life, and survival to see if personalized 3D-PTA-guided therapy improves outcomes. - Exclusions include distant metastasis, early-stage disease, other active cancers, significant organ or immune problems, active infection, or inability to take oral chemotherapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer is being studied. Conditions: Ovarian Neoplasms, Peritoneal Neoplasms • Eligibility: Inclusion Criteria: 1. Age: Women aged 19-85 years. 2. Diagnosis: Histologically confirmed ovarian, fallopian tube, or peritoneal cancer. 3. Platinum Status: * Refractory: Disease progression during platinum-based chemotherapy.…. Goal: The purpose of this study is to evaluate the tolerance, safety, efficacy, and pharmacokinetics of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with paclitaxel in patients with platinum-resistant recurrent ovarian cancer and peritoneal carcinomatosis. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Seoul National University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors is being studied. Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) • Eligibility: Key Inclusion Criteria: mCRPC cohorts (men): 1. Men with histologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma. 2. PSA value at screening ≥4…. Goal: The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has 2 parts. Phase/Status/Sponsor: Unknown phase; RECRUITING; Regeneron Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests adding elimusertib (BAY 1895344) to standard chemotherapy with cisplatin, or cisplatin plus gemcitabine, for adults with advanced solid tumors, including urothelial cancer. It is a dose-escalation phase I trial to find the safest and most effective dose and to learn how the combination behaves in the body. The trial will assess safety and tolerability, identify the maximum tolerated dose, and collect pharmacokinetics and early signs of activity, with a focus on urothelial cancer in the triplet arm. Eligible participants are adults 18 or older with measurable advanced disease for which cisplatin-based therapy is suitable; key exclusions include pregnancy, life expectancy under 6 weeks, uncontrolled illness, recent chemotherapy or radiotherapy, and certain drug interactions or prior ATR inhibitors. The study is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer is being studied. Conditions: Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer, Stage IV Liver Cancer • Eligibility: Inclusion Criteria: * Patient must be \>= 18 years of age * Patient must have a histologically confirmed diagnosis of combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CC) at the local laboratory…. Goal: This phase II trial compares the effect of adding bevacizumab and atezolizumab to gemcitabine and cisplatin (chemotherapy) versus chemotherapy and atezolizumab in treating patients with liver cancer that cannot be removed by surgery (unresectable) or that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) is being studied. Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7 • Eligibility: Inclusion Criteria: * Age \>= 18 years * Patients must have undergone complete surgical resection of their stage IB (\>= 4 cm), II or IIIA NSCLC according to…. Goal: This phase III ALCHEMIST treatment trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests the combination of nivolumab and ipilimumab in adults with rare cancers to see if it can shrink tumors or slow their growth. - It includes many different rare tumor types in separate groups, plus a PD-L1–amplified cohort that uses nivolumab alone, and it measures how often tumors respond using standard criteria. - The trial also looks at safety, overall survival, and progression-free survival across cohorts. - Eligible participants must have progressed after prior therapy and generally cannot have active brain metastases or uncontrolled autoimmune disease; some cohorts have additional specific requirements or exclusions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests adding tazemetostat to pembrolizumab for adults with locally advanced or metastatic urothelial carcinoma (cisplatin-resistant or platinum-ineligible). - The main goal is to find a safe dose for the combination and to see how well it works, including response rate, progression-free survival, and immune-related tumor responses. - The trial also includes correlative studies using tissue and blood to learn which patients may respond. - Key exclusions include prior PD-L1 or EZH2 inhibitors, active brain metastases (unless previously treated and stable), pregnancy or breastfeeding, and certain uncontrolled illnesses or recent cancer therapies.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This phase II trial tests whether adding venetoclax to ASTX727 (decitabine plus cedazuridine) improves outcomes for bone marrow cancer in CMML and MDS/MPN with excess blasts compared with ASTX727 alone. - It is for adults with MDS/MPN overlap syndrome with at least 5% marrow blasts who meet certain health criteria. - Participants are randomly assigned to either ASTX727 plus venetoclax or ASTX727 alone, and the study looks at complete remission rates and other response and survival measures. - Key exclusions include pregnancy, uncontrolled central nervous system disease, significant cardiac disease, recent extensive prior MDS/MPN therapy, and other safety-related conditions (e.g., grapefruit product restrictions).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is an exploratory study to see how the PET/CT tracer 68Ga-FAPi-46 distributes in normal and cancer tissue and how much it accumulates, with tissue validation. It includes adults with a variety of cancers who are planned for surgical resection or biopsy, to compare imaging results with the actual tumor tissue. The study aims to define biodistribution, measure PET uptake, and relate it to FAP levels and to other tracers like 18F-FDG (and, if available, DOTATATE or FDOPA). Exclusions include pregnancy or nursing, starting new cancer therapy between scans, or conditions that could interfere with data; the trial is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy is being studied. Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma +7 • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years old. 2. Body mass index (BMI) 18.5-40 kg/m\^2 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 4.…. Goal: This is a randomized, double-blind, fully controlled feeding study that will enroll melanoma patients starting standard-of-care ICB in three settings: adjuvant, neoadjuvant, and unresectable. Patients are randomized to the high fiber or healthy control diet. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma is being studied. Conditions: Liver Lymphoma, Mantle Cell Lymphoma • Eligibility: Inclusion Criteria: * Baseline measurements and evaluations must be obtained within 6 weeks of randomization to the study. Abnormal PET or CT scans may constitute evaluable disease. Patient…. Goal: This phase II trial compares three chemotherapy regimens consisting of bendamustine, rituximab, high dose cytarabine, and acalabrutinib and studies how well they work in treating patients with newly diagnosed mantle cell lymphoma. Drugs used in chemotherapy, such as bendamustine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; ECOG-ACRIN Cancer Research Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer is being studied. Conditions: Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8 +2 • Eligibility: Inclusion Criteria: * PRE-REGISTRATION (STEP 0) ELIGIBILITY CRITERIA: * BRAF V600 mutational status may be determined either locally or by central testing. This testing is mandatory prior to…. Goal: This phase II/III trial compares treatment with encorafenib and cetuximab to usual care (patient observation) for reducing the chance of cancer recurrence after standard surgery and chemotherapy in patients with BRAF-mutated stage IIB-III colon cancer. Encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Alliance for Clinical Trials in Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy is being studied. Conditions: Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Inflammatory Carcinoma +2 • Eligibility: Inclusion Criteria: 1. Is willing and able to provide written informed consent for the trial. 2. Is a female or male and \>/= 18 years of age 3.…. Goal: This phase II trial studies how well pembrolizumab works in treating patients with hormone receptor positive inflammatory breast cancer that has not spread to other parts of the body, who are receiving hormone therapy and did not achieve a pathological complete response to chemotherapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a not-yet-recruiting, single-arm Phase II trial testing whether Sintilimab plus Bevacizumab and AG chemotherapy can be given as first-line treatment for adults with unresectable locally advanced or metastatic cholangiocarcinoma. The study is for adults aged 18–75 who have surgically unresectable disease, no prior systemic therapy (except some postoperative therapy more than 6 months ago), and at least one measurable lesion. It aims to learn how often tumors respond, how many patients have disease control, how long responses last, overall survival, and safety, and it will also explore biomarker signals like PD-L1 and tumor mutational burden. Key exclusions include prior anti-PD-1/PD-L1 therapy, active autoimmune disease needing systemic treatment, HIV, active HBV or HCV infection, pregnancy, high bleeding risk, and recent major surgery.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas is being studied. Conditions: Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Follicular Helper T-Cell Lymphoma, Follicular-Type +3 • Eligibility: Inclusion Criteria: * Ability to understand and willingness to sign a written informed consent document * Documented informed consent of the participant and/or legally authorized representative. * Assent,…. Goal: This phase I trial tests the safety, side effects and best dose of ruxolitinib in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) chemotherapy and how well the combination works in treating patients with untreated nodal T-follicular helper (TFH) cell lymphoma. Ruxolitinib phosphate blocks a protein called janus kinase, which may help keep abnormal blood cells or cancer cells from growing. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria: 1. Have a full understanding of this study and voluntarily sign the informed consent form; 2. Aged 18 - 75 years; 3. Patients must be pathologically…. Goal: The goal of this clinical trial is to explore the preliminary efficacy and tolerability of Aipalolitovorelizumab (QL1706) in combination with fruquintinib for the treatment of metastatic colorectal cancer patients with immunodominant pMMR/MSS type who have failed second-line or above treatment. It is an open-label, single-arm, single-center phase II trial. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Harbin Medical University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests whether adding concurrent chemoradiotherapy after immunotherapy plus chemotherapy is safe and could help people with locally advanced esophageal squamous cell cancer. It is for adults with biopsy-confirmed squamous cell carcinoma whose cancer is locally advanced and not operable, or for whom surgery is refused. The study is a single-arm, exploratory trial designed to learn about safety and potential efficacy, not to compare treatments. Key exclusions include distant metastasis, prior thoracic radiation or chemotherapy or lobectomy, autoimmune disease, pregnancy, and certain serious health problems.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma is being studied. Conditions: Metastatic Pancreatic Ductal Adenocarcinoma • Eligibility: Inclusion Criteria: * Have histologically or cytologically confirmed PDAC that is metastatic. * Have not been previously treated for PDAC in the metastatic setting. 1. Prior neoadjuvant and/or…. Goal: The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Arcus Biosciences, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma is being studied. Conditions: Advanced Melanoma • Eligibility: Inclusion Criteria: To participate in the study, participants must meet all the following inclusion criteria: Cohort A only: 1. Prior treatment with anti-PD-(L)1 therapy (for example, pembrolizumab or…. Goal: This study is an open-label, 2-part, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab in participants with advanced cutaneous melanoma refractory to checkpoint inhibitor therapy. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Agenus Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs. is being studied. Conditions: Metastatic (Stage IV) Melanoma • Eligibility: Inclusion Criteria: In order to participate in the trial, all patients must meet all the following criteria: 1. Patient must have signed the written informed consent prior to…. Goal: Although treatments for breast cancer have improved, 20-30% of patients with early disease develop metastases (cancer that spreads to other parts of the body). Among the different types of breast cancer, hormone-sensitive cancers that do not overexpress the HER2 protein (HR+/HER2-) are the most common. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; UNICANCER.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations is being studied. Conditions: Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma • Eligibility: Inclusion Criteria: 1. ≥ 18 years of age at the time of signing the informed consent form (ICF). 2. Histologically or cytologically confirmed intrahepatic cholangiocarcinoma. 3. Subjects diagnosed…. Goal: This is an open-label, randomized, controlled, multicenter, phase III clinical study designed to evaluate the efficacy and safety of TT-00420 tablets as monotherapy versus chemotherapy in subjects with unresectable advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions/rearrangements or mutations, who have experienced recurrence or progression after prior first-line systemic chemotherapy. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; TransThera Sciences (Nanjing), Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

AB154 Combined With AB122 for Recurrent Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: 1. Grade IV glioma (glioblastoma and its variants according to the World Health Organization 2021), confirmed in tissue at time of initial diagnosis. Tumors with an…. Goal: This is a phase 0/I exploratory study. Patients at first or second recurrence of glioblastoma will be enrolled. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Yale University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests whether adding mifamurtide to post-operative chemotherapy improves outcomes for newly diagnosed high-risk osteosarcoma patients. It compares post-operative chemotherapy alone to post-operative chemotherapy plus mifamurtide in a multicenter, randomized, open-label design. Participants are people aged 2 to 50 with high-grade osteosarcoma who already had pre-operative chemotherapy and surgery and are considered high risk (metastases at diagnosis or poor histological response). Exclusions include low-grade osteosarcoma, active HIV or hepatitis infections, pregnancy, heart function issues, and other medical conditions that would preclude chemotherapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab is being studied. Conditions: Melanoma Stage III, Melanoma Stage IV • Eligibility: Inclusion Criteria: 1. Written Informed Consent and HIPAA Authorization 1. Subjects must have the nature of the study explained to them. 2. Subjects must be willing and able…. Goal: Cancers attract myeloid-derived suppressor cells (MDSCs) that prevent our own immune responses from destroying the cancer. This study will be the first study to begin to determine if the newly discovered drug SX-682 can block cancers from attracting MDSCs. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Syntrix Biosystems, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma is being studied. Conditions: Refractory Melanoma • Eligibility: Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and avail-ability for the duration of the study…. Goal: The goal of this clinical trial is to learn if DOC1021 + pIFN will be safe and will lead to tumor responses in patients with refractory melanoma. DOC1021 is a dendritic cell immunotherapy derived from a patient's own blood cells and loaded with antigens from the patient's tumor in the form of tumor lysate and mRNA. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Diakonos Oncology Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests the safety, tolerability, and potential effectiveness of giving durvalumab together with BCG (induction and maintenance) in adults with high-risk non-muscle-invasive bladder cancer who have not previously received BCG. - It targets adults in the United States whose high-risk NMIBC has been completely removed by TURBT and is confined to the lining of the bladder (Ta/T1). - The study is open-label and single-arm and aims to learn whether this combination can be safely given and whether it can improve cancer control during about two years of treatment, plus safety and survival follow-up. - Key exclusions include muscle-invasive or metastatic disease, active infections or autoimmune disorders, prior systemic immunotherapy, pregnancy, and certain other cancers or immunosuppressive conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss is being studied. Conditions: Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma • Eligibility: Inclusion Criteria: 1. Be willing and able to provide written informed consent for the trial. 2. Be \>/= 18 years of age on day of signing informed consent.…. Goal: The goal of this clinical research study is to learn if GSK2636771 given in combination with pembrolizumab can help to control the disease in patients with refractory (has not responded to treatment) metastatic melanoma. The safety of this drug combination will also be studied. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy is being studied. Conditions: Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer • Eligibility: Inclusion Criteria (applicable to all participants unless otherwise specified): * Cohort 1 only: Have histologically or cytologically confirmed ES-SCLC (using the American Joint Committee on Cancer \[AJCC\]) tumor…. Goal: This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or second-line treatment (Cohort 2 and Cohort 3). This study will assess the safety, efficacy, and pharmacokinetics (PK) of BNT327. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; BioNTech SE.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a Phase III, open-label, multicentre, randomized trial comparing dostarlimab with carboplatin-paclitaxel as first-line treatment for adults with MMR-deficient (MMRd/MSI-H) endometrial cancer that is recurrent or advanced. It is for women aged 18 and older with MMRd/MSI-H endometrial cancer who have measurable disease and ECOG 0-1. Randomization is 1:1 and stratified by prior adjuvant chemotherapy, prior pelvic radiotherapy, and whether the disease is newly diagnosed advanced/metastatic or relapse. Exclusion criteria include prior anti-PD-1/PD-L1 therapy, active brain metastases, certain active infections or autoimmune disease, and recent systemic anticancer therapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests whether adding serplulimab to FLOT chemotherapy improves the rate of complete tumor disappearance (pCR) in adults with stage III gastric adenocarcinoma. It compares serplulimab plus FLOT versus FLOT alone in a randomized design, for patients whose tumors are PD-L1 positive (CPS ≥ 1). Participants receive treatment every two weeks, have imaging at 4 and 8 weeks, then undergo surgery and may receive postoperative serplulimab with adjuvant chemotherapy or adjuvant chemotherapy alone. Key exclusions include HER2-positive tumors, MSI-H/dMMR, autoimmune disease, prior gastric cancer treatment, active infection or pregnancy. Status: ACTIVE_NOT_RECRUITING (the trial is active but not recruiting).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This phase Ib trial is testing whether regorafenib can be given safely with the standard chemotherapy for newly diagnosed Ewing sarcoma that has spread to multiple sites beyond the lungs or pleura. - It is for patients aged 2 to under 50 who have metastatic disease and are fit to receive the full multimodal treatment. - The study aims to find out if adding regorafenib is feasible and how to dose it during induction chemotherapy and consolidation chemotherapy, using different dose levels and timing around surgery or radiotherapy. - Key exclusions include disease limited to the lungs/pleura, pregnancy, prior ES treatment other than surgery, significant heart problems or uncontrolled high blood pressure, and other health issues that could interfere with treatment. - The trial is currently not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer is being studied. Conditions: Metastatic Pancreatic Cancer • Eligibility: Inclusion Criteria: * Voluntarily participate in the study and sign the informed consent form. * Male or female aged 18-80 years (inclusive) at the time of signing the…. Goal: This study plans to enroll participants with previously treated metastatic pancreatic cancer and harbor centrally confirmed KRAS G12D mutation. These participants are required to experience disease progression on or after at least one prior standard systemic therapy containing fluorouracil or gemcitabine, and either progressed on or were intolerant to the last treatment. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Genfleet Therapeutics (Shanghai) Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This randomized study tests whether adding ganitumab, a drug that blocks the IGF-1R pathway, to standard multiagent chemotherapy improves outcomes for newly diagnosed metastatic Ewing sarcoma. It is for patients whose cancer has spread to the lungs, bones, bone marrow, or other sites. The main goal is to see if event-free survival is better with ganitumab, and it also looks at overall survival and treatment toxicity, plus many exploratory biomarker and imaging studies to understand how the treatment works. Key exclusions include disease limited to regional lymph nodes, tumors in the brain or spinal cord, prior chemotherapy or radiation, pregnancy or contraception requirements for females of childbearing potential, diabetes, and chronic high-dose corticosteroid use.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma is being studied. Conditions: Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma • Eligibility: Inclusion Criteria: * PRE-REGISTRATION (STEP 0) * Histologically confirmed DLBCL expressing CD20 antigen; patients with transformed lymphoma are excluded; in this regard, patients with composite lymphoma in the…. Goal: This randomized phase II trial studies how well rituximab and combination chemotherapy with or without lenalidomide work in treating patients with newly diagnosed stage II-IV diffuse large B cell lymphoma. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

GYNORYLAQ-VLINIVAL is an early-phase, non-randomized, single-arm trial enrolling by invitation to test a personalized neoantigen vaccine for people with high-risk or recurrent endometrial cancer. The vaccine, called GYNORYLAQ-TM, is selected for each patient by the GYNORYLAQ-EC platform and given with individualized background cancer therapies chosen by the treating oncologist; the vaccine itself is investigational. The study aims to evaluate safety and tolerability and to assess the feasibility of manufacturing GMP-grade, patient-specific vaccine panels. Secondary goals include measuring vaccine-induced T-cell immune responses and exploring how the platform’s quantum/physics scores relate to clinical and immunologic outcomes. Eligibility requires confirmed high-risk or recurrent endometrial cancer with measurable disease; key exclusions include active uncontrolled infection, autoimmune disease requiring systemic immunosuppression, untreated CNS metastases, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers is being studied. Conditions: Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer +3 • Eligibility: Diagnosis and Main Criteria for Inclusion/Exclusion: Inclusion Criteria Main Study - patients with MSS mCRC These criteria are applicable for both Dose Escalation and Expansion part of the…. Goal: This Phase Ib/IIa study comprises a Main Study and a Study Extension. The Main Study has been designed according to a 3+3 Dose Escalation/dose Expansion design in refractory pMMR-MSS mCRC patients. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Rottapharm Biotech.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests Osimertinib plus chemotherapy as the first-line treatment for adults with EGFR mutation-positive NSCLC that is locally advanced or metastatic. - It aims to learn how well this combination works and how safe it is in real-world practice, by looking at investigator-reported progression-free survival and overall survival. - The study is sponsored by AstraZeneca and is currently active but not recruiting. - Eligible participants are adults 18+ with nonsquamous NSCLC and EGFR mutations Ex19del or L858R, at stage IIIB/IIIC or IV, who are considered appropriate for first-line Osimertinib plus chemotherapy by their physician (prior therapies allowed if meeting criteria). - Key exclusions include spinal cord compression or symptomatic brain metastases, a history of interstitial lung disease or active ILD, and other severe uncontrolled conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests EGFR-targeted CAR T cell therapy in children and young adults with relapsed or refractory non-CNS solid tumors that express EGFR. It has two arms: Arm A uses EGFR CAR T cells alone, and Arm B adds a CD19-targeting component. It is a phase I, open-label, non-randomized trial to assess safety and feasibility, determine the maximum tolerated dose, describe the toxicity, and see how long the CAR T cells persist and act against tumors. Eligible participants include those with EGFR-expressing non-CNS solid tumors that are recurrent or refractory; early enrollees are ages 15–30, with later enrollees ages 1–30. Key exclusions include active infection, other active cancers, active CNS disease, pregnancy, and GVHD or significant immunosuppression; if severe toxicity occurs, cetuximab or trastuzumab may be used to help eliminate the CAR T cells.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests whether adding two cycles of blinatumomab to standard chemotherapy improves disease-free survival in newly diagnosed B-ALL or B-lymphoblastic lymphoma, including people with Down syndrome. - It is for children and young people with these diseases, with age ranges defined by diagnosis (roughly up to age 10 for non-DS B-ALL and up to 31 years for DS B-ALL and B-LLy). - The trial aims to find out if blinatumomab plus chemotherapy works better than chemotherapy alone at preventing the cancer from returning, and to learn about long-term outcomes and safety, plus some exploratory immune and genetic factors. - Key exclusions include prior cytotoxic chemotherapy for the current cancer (with certain exceptions), certain CNS disease statuses, active testicular leukemia in non-DS patients, and pregnancy. - Sponsor: National Cancer Institute. Status: ACTIVE_NOT_RECRUITING.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors is being studied. Conditions: Non Small Cell Lung Cancer, ROS1-positive Non-Small Cell Lung Cancer (NSCLC) • Eligibility: Inclusion Criteria: 1. Age ≥18 years. 2. Histologically or cytologically confirmed locally advanced or metastatic NSCLC or other solid tumor with documented ROS1 rearrangement. 3. Previously received at…. Goal: The Expanded Access Program will provide an alternate mechanism for these patients, who lack satisfactory therapeutic alternatives and cannot participate in a zidesamtinib clinical trial, to access investigational zidesamtinib. Phase/Status/Sponsor: Unknown phase; AVAILABLE; Nuvalent Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.